ESC 2021 Highlights Podcast

 

In this episode, Medicom’s correspondent covers 6 presentations from the European Society of Cardiology (ESC) Congress, held 27-30 August 2021, followed by an exclusive interview with Prof. Stefan Anker (Charité Hospital, Berlin, Germany). The topics discussed are:

1. EMPEROR-Preserved proved to be a landmark trial in heart failure research. It demonstrated a clinically meaningful benefit of 21% reduction in the primary composite outcome as well as positive results in secondary outcomes with empagliflozin therapy for patients with heart failure with preserved ejection fraction (HFpEF).
2. ENVISAGE-TAVI, testing the direct oral anticoagulant (DOAC) edoxaban against a vitamin K antagonist post transcatheter aortic valve implantation (TAVI)  in patients with AF. This is the latest trial trying to carve out a role for a DOAC in this setting after GALILEO, ATLANTIS and POPular TAVI, Anticoagulation strategies for atrial fibrillation (AF) with either edoxaban or vitamin K antagonists were evaluated in patients post-TAVI in the ENVISAGE-TAVI AF trial. Edoxaban demonstrated non-inferiority in Net Adverse Clinical Events (NACE); however, due to a higher rate of major bleeding, there was no non-inferiority in the safety outcome within a very short period of time, you have now four major randomised clinical trials in the field of TAVI and antithrombotic therapy.
3. The TOMAHAWK trial compared immediate versus delayed angiography in patients with out-of-hospital cardiac arrest, is the largest trial to date to probe this important clinical dilemma.
4. Two antithrombotic studies of the investigational drug finerenone (FIGARO-DKD and FIDELITY) in chronic kidney disease and diabetes.
5. STEP addresses persistent questions about intensive versus standard blood-pressure lowering in older hypertensive patients.
6. The GUIDE-HF trial, presented in a Hot Line Session and simultaneously published in The Lancet, showed benefits of haemodynamic-guided heart failure (HF) management with an implantable device in reducing HF hospitalisation. However, no influence was observed on urgent HF visits and mortality.

Copyright ©2021 Medicom Medical Publishers



Posted on 14 September, 202126 October, 2021